Adjuvant therapy in breast cancer

Weekly paclitaxel adjuvant therapy for breast cancer may result in better overall survival than other regimens, the results of a US study suggest. A total of 4,950 women with axillary lymph node positive or high-risk lymph node negative breast cancer initially received four cycles of chemotherapy (doxorubicin and cyclophosphamide). They then received one of four adjuvant regimens: IV paclitaxel or docetaxel at three-week intervals for four cycles or at one-week intervals for 12 cycles. Estimated disease-free survival was 81.5 per cent for weekly paclitaxel, 81.2 per cent for three-weekly docetaxel, 77.6 per cent for weekly docetaxel and 76.9 per cent for three-weekly paclitaxel. However, weekly paclitaxel was associated with greater toxicity than the standard three-weekly paclitaxel regimen.

Sparano JA, Wang M, Martino S et al. N Engl J Med 2008;358:1663-71

Originally published in the June 2008 edition of MIMS Oncology & Palliative Care.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs